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Newcastle disease virus (NDV) is an avian virus that causes deadly infection to over 250 species of birds, including domestic and
wild-type, thus resulting in substantial losses to the poultry industry worldwide. Many reports have demonstrated the oncolytic
eﬀect of NDV towards human tumor cells. The interesting aspect of NDV is its ability to selectively replicate in cancer cells.
Some of the studies have undergone human clinical trials, and favorable results were obtained. Therefore, NDV strains can be the
potential therapeutic agent in cancer therapy. However, investigation on the therapeutic perspectives of NDV, especially human
immunological eﬀects, is still ongoing. This paper provides an overview of the current studies on the cytotoxic and anticancer
eﬀect of NDV via direct oncolysis eﬀects or immune stimulation. Safety of NDV strains applied for cancer immunotherapy is also
discussed in this paper.
1.Introduction
Cancer is a life-threatening disease characterized by uncon-
trolledcelldivisionleadingtoinvasionofsurroundingtissues
and metastasis. Cancers arise from both genetic and envi-
ronmental factors that lead to aberrant growth regulation of
stem cell populations, or by the dediﬀerentiation of more
mature cell types. Despite modern advance techniques in
diagnosis, prevention, and therapy, cancer is still aﬀecting
millions of patients worldwide and causing high mortality
[1].
In fact, cancer is a leading cause of death worldwide
which accounted for 7.9 million deaths (around 13% of
all deaths) in 2007 [2]. According to the report from the
National Cancer Registry Malaysia [3], the age-standardised
incidence rate (ASR) for all cancers in year 2006 was 131.3
per 100,000 people, regardless of sex and age. The ﬁve
most common cancers among the population of Peninsular
Malaysia in 2006 were breast, colorectal, lung, cervix, and
nasopharynx cancers.
The ideal cancer therapeutic is based on the selectively
killing of the malignant cells, while leaving normal tissues
intact. Currently, radiotherapy, chemotherapy, and surgery
are the most common treatments in cancer therapy. How-
ever, these therapies frequently lead to deleterious severe
side eﬀects [4]. Hence, it is important to develop a cancer
therapy with high eﬃcacy selectivity killing malignant cells
with fewer pitfalls. Virotherapy using oncolytic viruses had
been proposed as a potent cancer therapeutic. However,
the application of viruses in cancer therapy is still under
review. Thus, the focus of this paper relates to the safety and2 Journal of Biomedicine and Biotechnology
preclininal/clinical experiences of utilizing NDV strains in
cancer treatment.
2. Virotherapy
Seventy years ago, a lot of viruses have been discovered to
carry oncolytic activity against tumor cells. These viruses
include adenovirus, rabies virus, poliovirus, herpes simplex
virus, hepatitis A virus, inﬂuenza A virus, measles virus,
and NDV. Viruses can be genetically engineered to enhance
their cytolytic abilities. For example, recombinant oncolytic
herpes simplex virus that expresses DF3/MUC1 antigen
is replicated preferential in colon cancer liver metastasis,
rather than normal liver cells [5]. Several viruses are genetic
manipulated to speciﬁcally target the cancer cells. Introduc-
ing ONYX-015 (dl1520), a replication-selective adenovirus,
which had been modiﬁed by the deletion of the E1B-55-kd
region, enables the p53 proteins to maintain their functions
[6]. Therefore, the virus replication is dependent on the
expression of the p53 proteins. Thus, the virus replicating
is inhibited in cells with normal p53 function; in contrast,
malfunction of p53 proteins in tumor cells may lead to
replication and cell killing. In some cases, the virus is applied
in such a way that the virus attenuates in normal cells,
without aﬀecting its cytolytic ability towards tumor cells.
3. Immunotherapy
Immunotherapy refers to a new form of treatment strategies
which modulate the immune system to achieve a therapeutic
goal, including cancer treatment. Cancer immunotherapy
began in the late 1800s, where William Coley prepared a
mixed vaccine of streptococcal and staphylococcal bacteria,
known as Coley’s toxin, which helped to control or even
cure a few advanced cancers [7]. An immunomodulator
agent has the ability to augment immune defenses and treat
immunodeﬁciencies, cancer, infections and even autoim-
mune disorders [8]. One example is the introduction of the
tuberculosis vaccine, Bacillus Calmette-Guerin (BCG) that
can help to stimulate the immune system and eradicate lung
carcinoma [9].
Immunotherapy exploits the properties of the immune
system, which involves the white blood cells (WBC), such as
natural killer (NK) cells, and T and B lymphocytes. The B
lymphocytes produce antibodies targeting foreign antigens.
The T lymphocytes are activated by other cells, as well as
secrete cytokines useful for cell activation, proliferation, and
diﬀerentiation, in response to speciﬁc invader antigens. NK
cells are activated by the cytokines, in response to tumor cells
andpathogens.ActivatedNKcellsalsosecretecytokinessuch
as interferon (IFN), interleukin (IL), tumor necrosis factor
(TNF), and others [10, 11].
4.Newcastle Disease Virus
Newcastle disease (ND) was the name given to a highly
pathogenic disease when occurred in England by Alexander
[12]. This disease has plagued the poultry industry since it
was ﬁrst recognized in 1926. It was caused by NDV, a virus
category in the family Paramyxoviridae and genus Avulavirus
[13]. NDV is also named as avian Paramyxovirus type 1
(APMV-1) virus [14]. NDV causes a deadly infection in over
250 species of birds, both domestic and wild, resulting in
substantial losses to the poultry industry worldwide.
In fact, NDV naturally infects via respiratory and ali-
mentary tract mucosal surfaces. In laying ﬂocks, a sudden
drop in egg production with a high proportion of eggs laid
with irregular (soft) or misshapen shells are often early signs
of the disease. Severe virus infection may lead to sudden
death. After lesions, edema of the interstitial or peritracheal
tissues of the neck may be presented, especially near the
thoracic inlet. The symptoms are variable, depending on the
virus strain, bird species, concurrent disease, and preexisting
immunity [13, 14].
Newcastle disease virus (NDV) strains can be divided
into three diﬀerent pathotypes based on their virulence and
severity of disease. Highly contagious velogenic strains are
divided into viscerotropic and neurotropic velogenic strains.
Viscerotropic velogenic viruses are responsible for acute
lethal infections, resulted haemorrhagic, and necrotic lesions
in the intestines of dead birds. Whereas, neurotropic velo-
genic viruses cause high mortality, follows with respiratory
and neurological disease, but absence of gut lesions. Meso-
genic strains resulted in respiratory and nervous symptoms
causing moderate mortality; while lentogenic NDV strains
cause mild infections of the respiratory tract in adult birds
and are considered of low virulence [14].
Infection of NDV in the host cells is depending on
two glycoproteins embedded in the viral lipid membrane,
which are hemagglutinin-neuraminidase (HN) and fusion
(F) glycoproteins that assist in virus infection. Initially,
NDV infection ensues by attachment to the target cell
through HN protein and sialic acid-containing receptors
[15]. Upon adsorption of the HN to its cellular receptors,
NDV undergoes conformational changes, which in turn
triggers F protein conformational change and releases the
fusionpeptides tofusetheviraland cellularmembranes. The
F glycoprotein precursor (F0) was proteolytically cleaved to
the disulﬁde link and formed infectious particles, F1 and F2
[15, 16]. Finally, the penetration of NDV to target cells is by
the endocytosis process [17].
5. Potentialof Newcastle Disease Virusin
Cancer Treatment
Like other viruses, NDV infects the host cells and then
replicates itself. Scientists are interested in NDV because it
can replicate itself more quickly in human tumor cells than
in normal cells and cause oncolytic eﬀects [18]. The NDV
strains can replicate up to 10000 times better in human
neoplastically transformed cells than in most normal human
cells [19, 20]. The selective eﬀect was probably due to the
host restriction of V protein and virus-induced cytokines
(IFN-γ and TNF-α)[ 21, 22]. The majority of tumor cells
could be infected by NDV, and the viral replication within
was detected by the increase of viral antigens on the cellJournal of Biomedicine and Biotechnology 3
surface [23]. Thus, theoncolytic eﬀect of NDV on human
tumor cells is validated.
TheﬁrstreportoftheapplicationofNDVtotreathuman
cancers was in the early 1950s, when adenovirus and NDV
were injected directly into uterine carcinoma, resulting in
partial necrosis and sloughing, but followed by regrowth
[24]. This might be due to the production of neutralizing
antibodies that inhibited the oncolytic activity of NDV. After
that, many reports showed the possibility of NDV as a
therapeutic agent in cancer treatment, from studies both in
mouse models and in human clinical trials which showed
favorable results [22, 25, 26].
The advantages of using NDV in cancer treatment are
summarized as below.
(1) Ability of virus to bind to the tumor cell surface via
its HN glycoprotein.
(2) Virus replicating in infected tumor cells leads to an
enhanced expression of viral antigen on tumor cell
surfaces.
(3) Ability of virus to induce synthesis of cytokines, like
IFN and TNF, as well as stimulates production of
heat shock proteins, adrenocorticotropic hormone,
and tissue inhibitor of metalloproteases.
(4) Pleiotropic immunostimulatory eﬀects of virus as
the virus can augment the eﬀects of T helper (TH)
cells, cytotoxic T lymphocyte (CTL), NK cells, and
macrophages.
(5) Oncolytic activity or direct killing of tumor cells in
treated patients.
(6) Rapid growth of virus in tumor cells.
(7) The virus is not pathogenic to humans.
6. Immunostimulatory Property of NDV
Although NDV causes direct oncolysis eﬀects on tumor cells,
NDV has the ability to modulate the human immune system
(Table 1). Zorn et al. [27] showed that cellular cytotoxicity of
peripheral blood mononuclear cells (PBMC) was enhanced
signiﬁcantly, after coincubation of NDV with eﬀector cells.
Throughout the study, NK cells were found to be the
predominant mediator of lysis.
Indeed, NDV had been found to stimulate the host
immunity to produce cytokines, such as IFN-α,IFN-β,T N F -
α, and IL-1, which in turn leads to the activation of NK cells,
macrophages,andsensitizedTcells[19,28,29].Accordingto
Fournier et al. [21], paracrine stimulation of IFN responses
is through either exposure of viral HN proteins or by viral
RNA. This virus-induced IFN-α/β is a potent inducer of NK
cell-mediated cytotoxicity through induction of TNF-related
apoptosis-inducing ligand (TRAIL) [30, 31]. Therefore,
activated NK cells are considered as important contributors
to innate defense against viral infections. Besides, IFN-α/β
is also important in the generation of CTL activity [32].
The IFN-α released also functions for stimulation of cell-
mediated cytotoxicity [33].
Human NK cells can be activated by NDV and lead
to augmentation of antitumor cytotoxic activity towards
tumor cells. Activated NK cells exert signiﬁcant in vitro
bystander antitumor activity, when stimulation cultures are
performed on human tumor cell monolayers [34]. Adaptive
transferofthestimulatedcultureintoimmunodeﬁcientmice
bearing human breast carcinoma has resulted in tumor
regression [34]. According to Jarahian et al. [35], NK cells
can be activated through direct interaction between the
HN viral glycoprotein and sialic acid residue containing
in the cell surface. In fact, HN has been found to be a
potent inducer of IFN production by human PBMC and is
capable of upregulating the TNF-related apoptosis inducing
ligands (TRAIL) [36]. Thus, activated NK cells are capable
of stimulating cytokines secretion, such as IL-2, IFN-γ,a n d
TNF-α, further inﬂuencing and activating other immune
cells’ functions. Importantly, NK cells display its ability to
kill tumor cells independent with MHC class I molecule
expressed on target cell surface. Therefore, it is acceptable to
speculate that activated NK cells have more cytolysis eﬀect
against tumor cells.
NDV infection results in potent upregulation of major
histocompatibility complex (MHC) class I molecules,
antigen recognition molecules (HLA), and cell adhesion
molecules (intracellular adhesion molecules (ICAM)-I and
lymphocyte function-associated antigen (LFA)-3) on the
tumor cell surface [37, 38]. Moreover, NDV infection leads
to an increasing T cell costimulatory activity; consequently,
enhanced cytotoxic potential of eﬀector cells [37, 39, 40].
NDV-infected melanoma cells not only completely restored
the proliferative response of the T helper (TH) cells, but
also prevented induction of anergy [40]. In addition, NDV
induces production of various cytokines (IFN-α)a sw e l l
as chemokines (RANTES and IFN-γ inducible protein
10 (IP-10)), ﬁnally undergo apoptosis [33, 39]. These
chemokines function to chemotaxis as well as inﬂuence the
activation status and cytotoxic activity of various immune
cells [36].
Recently, it was shown that double-stranded RNA
(dsRNA) is recognized by dendritic cells that have high
expression of toll-like receptor (TLR)-3 that lead to matu-
ration, activation, and protection [41–43]. NDV can activate
macrophages and upregulate various macrophage enzymes,
such as adenosine deaminase (ADA), inducible nitric oxide
synthase (iNOS), lysozyme, and acid phosphatase. Through
danger signals, activated dendritic cells promote cross-
priming of T cells [33, 44, 45]. Activated dendritic cells
increase their expressions of costimulatory molecules and
stimulate T-cell response [43]. Also, NDV induces pro-
duction of antitumor eﬀector molecules, like nitric oxide
(NO) and TNF. NDV administration also induce interferon
(IFN) secretion,which further enhanced the phagocytosis of
opsonized erythrocytes by mouse peritoneal macrophages
[46]. The enhancement of phagocytosis activity might
correlate with the stimulation of NO synthesis and the
activation of NF-κB in macrophages which have important
roles in mediating cytotoxicity [29]. Some encouraging
results obtained by using NDV-activated macrophages to
treat mammary carcinoma and lung carcinoma in vitro [47].4 Journal of Biomedicine and Biotechnology
Table 1: Summary of the immunological properties of NDV.
Immunity Consequences
Innate immunity
Apoptotic bodies lead to dendritic cell activation: augmentation of macrophage phagocytosis ability.
Chemokines induction (RANTES and IP-10): stimulates chemotaxis, as well as recruitment of monocytes and
Tc e l l s .
Virus progeny resulted in monocyte activation: increased synthesis of NF-κB, NO, TRAIL, and augmentation
of cytotoxic eﬀect.
Adaptive immunity
T cells costimulation: upregulated MHC molecules expression, enhanced antigen presentation, and increased
expression of cell adhesion molecules, such as ICAM-1 and LFA-3 molecules.
Expression of viral HN molecules: increased production of IFN-α and TRAIL.
Presence of double-stranded RNA: stimulation of TLR-3, IFN-α and heat shock protein expression.
Also, NDV exerts an immunostimulatory eﬀect on
monocytes. Upregulation of TRAIL mediated the tumorici-
dal activity of human monocytes, upon stimulation by NDV
[33]. After 14 hours of coincubation, activated monocytes
exertedantitumorcytotoxicactivitytowardsTRAIL-sensitive
tumor cells. Meanwhile, virus-stimulated PBMC mediated
antibody-dependent cellular cytotoxicity (ADCC) through
the Fc receptors of the antibody expressed.
In summary, NDV has very strong immunostimulatory
propertiesforthegenerationofantitumorimmuneresponse.
Through direct contact with eﬀector cells, NDV caused
cell activation, proliferation, and development. Besides, the
cytokines produced also play an important role in the
augmentation of immune responses.
7. ClinicalExperiencewith
Different Strains of NDV
The NDV strains that have been most widely evaluated
for the treatment of human neoplasms are the nonlytic
strain Ulster, as well as, the lytic strains MTH68/H, PV-
701 and 73-T. Diﬀerent virus strains may show various
degrees of cytotoxic eﬀects and viral production. When a
nonlytic NDV strain is used to infect monolayer tumor cells,
production of noninfectious viral particles was observed; in
contrast, lytic NDV strains caused production of infectious
particles that can infect other tumor cells, thus leading
to an ampliﬁcation of the viral load. Besides, infection of
lytic NDV strains resulted in syncytium promotion and
plague generation on tumor cell monolayers. The nonlytic
strain Ulster showed stronger cytotoxic eﬀects against colon
carcinoma;incontrast,thelyticstrainItaliencausedeﬀective
killing of human melanomas [48].
Moreover, NDV possessed cytotoxic eﬀects on tumor
cells through two important components: exposure of the
viral HN protein to the antigen-presented or tumor cell
surface, facilitating the interaction between immune cells
and tumor cells [49] and local induction of cytokines (type
I IFN), which function for cell migration, activation and
diﬀerentiation [32]. This statement was proven by the study
by Li et al. [50], where the recombinant fowlpox virus which
expressed NDV viral HN gene had enhanced cytotoxic eﬀect
onB16tumorcells.In vivo vaccinationcausedthepercentage
of CD4 and CD8 T cells markedly increased, and also
enhanced tumor-speciﬁc CTL activity. In addition, higher
level of IFN-γ was secreted by T cells from the immunized
mice that indicated the recombinant virus promoted TH1-
dominant response [50].
There are diﬀerent conceptual applications of NDV in
cancer and disease treatments like
(1) use for tumor selective cytolysis (oncolysis) [19];
(2) use of NDV as an adjuvant in a tumor vaccine for
stimulationofCTLanddelayed-typehypersensitivity
(DTH) responses after antitumor vaccination [20];
(3) use of NDV for nonspeciﬁc immune stimulation and
induction of cytokines, like interferons [36, 39];
(4) use of NDV as viral vector for delivering therapeutic
genes [51];
(5) use of NDV as vaccine vector for immunization
against emerging pathogens [52].
8.NDV OncolysatewithStrain73-T
Viral oncolysate was prepared by using primary explants
of human tumor cells incubated with NDV [53]. Since the
mid-1950s, NDV lysate started to be administered to cancer
patients. The oncolysate functioned to augment antitumor
immunologic responses towards metastatic disease. Admin-
istration of oncolysate to the patients resulted in increased of
T lymphocyte percentage and enhanced cytotoxicity.
Initially, viral oncolysate was prepared by using the lytic
NDV strain 73-T [24]. The virus was obtained by passaging
of NDV strain 379-SI on Ehrlich ascites tumor cells in
vitro for 73 times and in vivo for 13 times, in a reason to
eliminate the neurotrophic properties of the strain. NDV
strain 73-T has the ability to replicate in human tumor cells,
causing cell-cell fusion, syncytium formation and tumor cell
death [54]. In vitro, the virus kills many human cancer cells,
such as ﬁbrosarcoma, osteosarcoma, neuroblastoma, cervical
carcinoma, Wilm’s tumor, and so on [55]. In addition, the
oncolytic potency of NDV strain 73-T was demonstrated
in mice with human tumor xenograft models. Intratumoral
and intraperitoneal injection of NDV strain 73-T caused
durable, complete tumor regression in athymic mice bearing
human neuroblastomas and ﬁbrosarcoma xenografts [55].
More than 67% inhibition of tumor growth was observed,
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showed locally administered virus was able to inhibit tumor
growth (77 to 96%) in several carcinoma xenografts in mice,
including cancer of epidermoid, colon, lung, breast, and
prostate xenografts. Furthermore, complete tumor regres-
sion was observed in 9 of 12 mice bearing IMR-32 neu-
roblastoma tumor xenografts, after a single intraperitoneal
injection of NDV. Most important of all, this strain did not
cause any adverse eﬀe c to nn o r m a lh u m a nc e l l s[ 55].
The ﬁrst clinical documentation of NDV activity was
reported by Cassel and Garrett [24], involving one cervical
cancer patient. In this paper, the 2.4 × 1012 virus par-
ticles were injected directly into the tumor demonstrated
intratumoral regression of the local cancer and also a
distant malignant lymph node [24]. Partial necrosis and
sloughing were observed, but this was followed by tumor
regrowth. Following this study, a phase II clinical trial
with administration of viral oncolysates was performed for
patients with malignant melanoma [57]. As a result, 6 out of
13 patients showed a decrease in the size of the skin nodules
and/or lymph node lesions.
Cassel et al. [58] did phase II clinical trials comprising of
32 patients at high-risk stage II melanoma, viral oncolysate
was administered, following surgical excision of metastatic
nodes. After the treatment, it was observed that progressive
disease occurred in only 6%, 8%, and 12% of patients. In
another clinical trial which involved 83 patients at stage II
malignant melanoma, NDV oncolysate was applied as an
immunotherapeutic agent in postsurgical management [59].
The patients were observed for at least 10 years with over
60% are survived and free of recurrent disease. The survival
rate was signiﬁcantly higher than historical controls. This
indicatedthattheNDVoncolysatewashelpfulasanadjuvant
to surgery in the management of malignant melanoma.
Furthermore, a 15-year follow-up phase II clinical trial
initiated in 1975 on patients with stage III malignant
melanomatreatedwithNDVoncolysateindicatedmorethan
60% often-yearsurvivalwithoutanyadverse eﬀects.Contin-
ued analysis of the trial showed 55% of overall ﬁfteen-year
survival. Extended survival was observed among patients
who displayed an increase in the number of CD8+ CD56+ T
lymphocytes, as these cells provide eﬀective immune defense
against tumor cells. In addition, the increased cells also
produced large amounts of cytokines, like TNF-α and IFN-γ,
to aid in cytotoxicity [60].
9.Autologous Tumor-CellVaccine(ATV)with
NDV StrainUlster
Besides NDV oncolysate, a new strategy for the design of a
human tumor vaccine was developed by Liebrich et al. [61].
The tumor vaccine consisted of patient-derived autologous
live tumor cells inactivated by irradiation and then infected
by the nonlytic NDV strain Ulster. Then, the vaccine was
stored in liquid nitrogen until application. The idea of autol-
ogous tumor-cell (ATV) vaccine had come from the study of
virus-modiﬁedEsbcellstotreatlymphomainanimalmodels
[62, 63]. Viral modiﬁcation leads to an increase of tumor
cell immunogenicity [62]. The vaccine was used as challenge
for a new antimetastatic therapy strategy, as chemotherapy
d r u g sb e c a m el e s se ﬀective. Postoperative vaccination with
virus-modiﬁed ESb cells was able to give protection from
metastases in more than 50% of syngeneic mice [63]. The
surviving mice developed long-lasting protective immunity
towards lymphoma, due to the immune T-cell memory
system. Schild et al. [64] had described the enhancing of
T-cell immune activity, upon immunization using NDV-
modiﬁedtumorcells.Also,theproductionofcytokines,such
as IL-2 and IFN-α/β, was increased after antigen stimulation.
These cytokines were essential for the generation of tumor-
speciﬁc CTL activity [32].
To prepare the ATV-NDV vaccine, nonlytic strain Ulster
is used in the culture of patient-derived tumor cells. The
selection of this strain was based on several reasons. First,
it is an RNA virus, which cannot integrate into the host cells’
genome. NDV replicates selectively in the tumor cells, but
not normal cells [24, 54]. Besides, NDV possesses pleiotropic
immunomodulatory properties [27, 33]. There are a lot
of successful test cases in preclinical and clinical studies,
without any severe side eﬀects [55, 58, 59, 63].
NDV strain Ulster has a monocyclic abortive replication
cycle in tumor cells [20]. The virus ﬁrst is adsorbed on to the
tumor cells, taking about an hour for binding. The virus is
allowed to remain in the body for a generation for eﬀective
immune responses, most probably T-cell-mediated immu-
nity. Direct contact of virus with immune cells will aﬀect cell
proliferation and activation status. As viral replication takes
a b o u t1 0t o5 0h o u r si nt u m o rc e l l s ,i ti ss u ﬃcient for the
generation of DTH skin responses [20].
Clinically, the ATV-NDV was tested in 23 patients with
colorectal liver metastases. Vaccination was applied to the
patients after they underwent liver resection [61]. As a result,
the patients showed increased recurrence-free intervals and
DTH skin reactivity. In another study, favorable results
were obtained by using ATV-NDV, comprising of a dose
of 1 × 107 human colorectal tumor cells together with 32
hemagglutination units (HAU) of NDV, intracutaneously
administered to colorectal cancer patients [65]. After four
vaccinations at two-week intervals, the DTH responses were
increased at distant sites. This indicated an augmentation of
tumor reactive T lymphocytes.
The study was continued by a clinical study in 20
colorectal cancer patients after surgical resection of the
tumor [66]. The ATV-NDV vaccine was prepared with
diﬀerent numbers of tumor cells ranging from 2 × 106 up to
2 × 107 cells, and NDV concentrations from 4 to 64 HAU.
Overall, 16 patients responded with a DTH skin response
after vaccination. After 24 hours, optimal skin reactions
were observed with 1 × 107 tumor cells infected with 32
HAU of NDV strain Ulster [66, 67]. This means that the
presence of low amounts of antigen was enough to induce
local memory immune response of cancer patients. Then,
phase II clinical trial was undertaken in postoperative active-
speciﬁc immunization (ASI) with ATV-NDV to 23 colorectal
carcinoma patients following resection of liver metastases
[67]. Encouraging results were obtained as the vaccinated
group experienced lower recurrence rate, compared to a
historically matched control group.6 Journal of Biomedicine and Biotechnology
Long-term survival rate of vaccinated patients was
reported by Kirchner et al. [68].ATV-NDVwasusedasasur-
gical adjuvant vaccine for 208 patients with locally advanced
renal cell cancer. Vaccination caused a median disease-free
survival of 21 months, higher than the historical controls
[68].Withatwo-yearfollowup,theanalysisshowedthatonly
10 relapses (18%) among the patients, along with a median
followup of 39 months. Another study involved a group
of 48 cancer patients; the vaccinated patients experienced
97.9% of two-year survival rate, higher than the historical
control [69]. Besides, encouraging results were obtained in
a nonrandomized study involving 23 glioblastoma patients
vaccinated by ATV-NDV [70]. The results showed that
vaccination lead to improvement of the median survivalrate,
signiﬁcantly higher than the control group.
Another study in China indicated the eﬃciency of NDV
vaccination as adjuvant after tumor cell resection. A total
of 310 colorectal cancer patients with resection received
ATV and NDV strain LaSota vaccine as adjuvant [71].
The results showed that advanced tumors of the digestive
tract signiﬁcantly regressed upon vaccination. The one year
survival rate of the vaccinated patients was 96%. Followup
of the vaccinated patients showed 56.5% in seven-year
survival rate, compared to the control group (43.42%). After
vaccination, the total eﬀective rate (complete and partial
remission) was 24%, including one case of complete tumor
remission[71].Mostimportantofall,thevaccineaugmented
immune activities by increase the number of NK cells.
In a colorectal carcinoma study, the high quality of
the ATV-NDV vaccine caused a 25% increase in the 5-
year survival rate [72]. Similar results were obtained in a
recent study involving 51 colorectal cancer patients with liver
metastasis [73]. A total of 6 doses of vaccination showed
improvement of metastasis-free survival rate. Vaccinated
patients had better survival rate (48% above the control
group).Allvaccinationsweretolerated[73].Only16%ofthe
vaccinated patients experienced minor side eﬀects, including
local erythema and itching at the injection site. A single case
reportedheadachesontheﬁrstvaccinationday,butitdidnot
recur for the subsequent vaccinations.
The quality of the ATV-NDV vaccine is critical for
antitumor eﬃciency. This was proven in the study by
Schirrmacher [72] that the high quality vaccine showed
36% higher eﬃcacy than the low quality one, in terms of
ﬁve-year survival rate in an advanced breast cancer study.
Hence, improvement of the quality and eﬃcacy of ATV-
NDV vaccine was carried out. Ockert et al. [69] modiﬁed the
vaccine preparation step by enrichment of the tumor cells
through Percoll centrifugation, followed by the removal of
tumor-inﬁltrating leukocytes (TIL) using immunomagnetic
beads.Besides, improvement ofantitumor eﬃciencyof ATV-
NDV vaccine could be achieved in another way, by the
addition of recombinant IL-2 [74, 75]. Vaccinated patients
beneﬁted with improved survival rate, with three-year and
ﬁve-year survival rates of 67% and 61%, respectively [75]. A
signiﬁcant number of patients had increased tumor-speciﬁc
T lymphocytes, even after 5 to 6 years after vaccination,
thus conferring antitumor immunity. In another study, the
antitumor eﬃciency of ATV-NDV was enhanced with the
aid of recombinant bispeciﬁc hybrid antibodies [37]. The
antibodies-coated ATV-NDV caused upregulation of T cell
activation markers (CD3 and CD28) within 24 hours.
In summary, the ATV-NDV vaccine appeared to be
feasible and safe to treat advanced cancers such as colorectal
cancer, breast cancer, ovarian cancer, glioblastoma, kidney
cancer, and head and neck cancer [65, 70, 72, 75, 76].
Continuous eﬀorts for the improvement of the tumor
vaccine quality are carried out in order to improve the
prognosis for survival of vaccinated patients.
10. PV701 Strain
PV701 strain is a nonrecombinant, replication-competent
NDV isolated by investigators at Pro-Virus Inc. (Gaithers-
burg, USA). It is a naturally attenuated, triple-plaque-
puriﬁed isolate from the mesogenic NDV strain MK107.
The broad-spectrum oncolytic activity of this virus strain is
probably due to tumor-speciﬁc defects in the IFN antiviral
response. This NDV strain is considered to be tumor
selective, as it is sensitive to most human cancer cell lines,
depicting a two-to-four log order higher sensitivity than to
normal cells [19].
TheoncolyticeﬀectofNDVstrainPV701wasreportedin
the study by Lorence et al. [77]. Intravenous administration
of PV701 in a dose-escalation study in tumor-bearing mice
produced partial tumor regressions at doses as low as
6 × 105 plague forming unit (pfu). More than 80% of the
mice developed complete tumor regressions at doses up to
6 × 108 pfu. The antitumor response was associated with
evidence of viral replication.
These encouraging results led to initiation of a phase
I clinical trial to intravenously administer PV701 strain to
advanced solid cancer patients. Intravenous administration
of NDV strain PV701 vaccine was done on 79 patients with
solid tumors [19]. A maximum tolerated dose (MTD) fol-
lowing a lowed initial desensitized dose at 12 × 109 pfu/m2;
and subsequent infusions were increased 10 folds, tolerated
up to 120 × 109 pfu/m2 [19, 78]. Further dose escalation
on the patients would lead to hypotension. In this study,
the virus strain caused regression of advanced solid cancers,
without observed cumulative toxicity [19]. One patient’s
squamouscellcanceronhistonsilwascompletelyeliminated
after vaccination. Measurable tumor reductions were seen
in another seven patients with diverse malignancies [19].
Unfortunately,onepossiblytreatment-relateddeathinvolved
a renal cancer patient with lung metastatic [19]. Post-
mortemrevealedinﬂammationoccurredinlungs,suggesting
rapid tumor lysis leading to compromised pulmonary func-
tion after vaccination.
More work is required to improve patient’s tolerance.
Therefore, following the phase I trial, some modiﬁcations
were performed by Laurie et al. [79]. Two-step desensitiza-
tion was implemented by using two dose increments, before
high repeat dosage. As a result, a patient with anal carcinoma
experienced tumor regression and four patients had stabi-
lization of their disease for more than 6 months. Primarily,
the ﬁrst dose of desensitization allowed higher tolerance ofJournal of Biomedicine and Biotechnology 7
subsequent doses [78, 80]. Hotte et al. [78] modiﬁed the
vaccination scheme by introducing slow infusion, in order to
improve patient tolerance. The MTD for initial slow infusion
was 24 × 109 pfu/m2 and subsequent infusions were safely
escalated to 120 × 109 pfu/m2 [78]. A total of 54% patients
survived over 4 months of progression-free intervals, after
vaccination. 15 out Of 18 treated patients, developed stable
disease, including 4 major and 2 minor tumor responses
[78]. Phase II continuous studies are ongoing for patients
with cancer resistant to conventional modalities.
In summary, NDV strain PV-701 well tolerated an
intravenous dosage of at least 3 × 109 infectious units and
at least 4 × 1012 infectious units by intratumoral route [78].
The developments of two complementary strategies, namely,
desensitization and slow infusion, have led to improvement
of the vaccine with reduced toxicity. So far, favorable results
were observed when using the virus to treat diverse human
cancers. Generally, the mild side eﬀects observed were
ﬂu-like symptoms, tumor-site-speciﬁc adverse events, and
infusion reactions [19, 79, 80]. The adverse eﬀects were
dose-dependent. Of the seven patients with noncardiac chest
and/or back pain, ﬁve among them received highest dosage
[79]. Other typical side eﬀects observed in some patients
were leucopenia and neutropenia. Occasionally, virus infec-
tion was associated with transient thrombocytopenia and
diﬀuses vascular leakage [19]. Presence of viral particles
was observed in the tumor tissue of vaccinated patients,
but not in heart, lung, kidney, liver, or brain tissue [19,
77]. Virtually, most of the vaccinated patients developed
neutralizing antibodies towards NDV strain PV701. Besides,
viable virus was recovered from the urine of vaccinated
patients, and rarely in sputum, but the virus recovery did not
persist and was cleared within 3 weeks.
11. MTH-68/H Derivedfrom
the Hertfordshire Strain
The mesogenic NDV strain Hertfordshire was isolated in
England in 1933, and later known as Herts’33. Early study
by Alexander et al. [81] reported the cytopathogenicity and
production of NDV stain Herts’33 progeny in animal cell
lines. Virus infection at low multiplicities caused cell fusion
within 24 hours; while at high multiplicities, the eﬀects
were induced within 3 hours after infection. Among these
cells, virus replication happened in MDBK cells, chicken
embryo cells, and baby hamster kidney clone (BHK-21)
cells. Meanwhile, NDV caused more cell lysis to Madin-
Darbybovinekidney(MDBK)cells,aslactatedehydrogenase
(LDH) was released in large amount after 24 hours of
infection.
The ﬁrst intensive use of NDV strain Hertfordshire
for cancer treatment was pioneered by Csatary [82]. He
developedanovelvirusstrainnamedMTH-68,whichmeans
“More Than Hope 1968.” Since then, many researchers
started to investigate its anticancer ability. MTH-68/H strain
has the ability to cause signiﬁcant regressions of human
tumor cell lines in varying degrees, such as PC12, MCF-
7, HCT116, DU-145, HT-29, A431, HELA, and PC3 cells.
Activation of caspase 8- and 9-induced apoptosis on the
virus-infected cells, irrespective of their p53 conditions [83].
Indeed, MTH-68/H was the most potent IFN-α inducer
among all NDV strains tested [84]. Besides, this NDV strain
also has the ability to induce nitric oxide (NO) and to
increase the macrophage population in treated rats, resulting
in enhancement of antitumor eﬀects [85].
Clinically, in one placebo-controlled trial, the MTH-
68 vaccine was administrated to 33 patients with advanced
cancers in the way of inhalation twice weekly [25]. Favorable
responses occurred in a total of 18 patients (55 %) compared
to 2 patients in the placebo group (only 8 %), as the tumor
stably regressed [25]. Seven vaccinated patients survived
more than 2 years, whereas none from the control group.
An individual case of vaccination of NDV strain MTH-
68/H to a 14-year-old patient with high grade glioblas-
toma was reported in 1999. The patient received adjuvant
chemotherapy, after tumor resection and radiation therapy.
IneﬃcienttumorclearanceforcedthepatienttoreceiveNDV
vaccine. During that time, the patient continued receiving
tamoxifen as adjuvant. As a result, the tumor progressive
shrunk by about 95% from the scan, without any neurotoxic
eﬀects [86]. This breakthrough case of complete remission of
tumor indicates that NDV vaccine may be a potent cancer
treatment.
A recent study showed that ultraviolet light (UV)
inactivated MTH-68/H was a potent interferon-α inducer
and could induce human PBMC antitumor activity in vitro
[84]. Therefore, Apostolidis et al. [84] utilized locoregional
therapy for the treatment of liver metastases of luciferase-
transfected murine CT26 colon carcinoma cells. As a result,
NDV strain MTH68/H caused a signiﬁcant delay in tumor
growth and prolonged survival, without severe side eﬀects.
Lossofbodyweightdidnotoccuramongthevaccinatedmice
[84].
12. Other NDV Strains
The NDV strain HUJ (OV001) is a lentogenic strain, which
is highly puriﬁed, isolate originally derived from naturally
attenuated B1 NDV vaccine strain. This strain has high
selective cytopathogenicity to human and animal cancer cell
lines. Virus infection leads to viral replication producing
virus progeny. However, the virus progenies produced by the
lentogenic strain are noninfectious, because of incomplete
processing of the fusion (F) protein. Besides direct cytotoxic
eﬀectsontargetcells,NDVstrainHUJalsoinducescytokine-
mediated events and augments the immune reactions [87].
In a recent phase I/II trial, NDV strain HUJ was admin-
istered intravenously to 11 patients with recurrent glioblas-
toma multiforme (GBM). Following biweekly maintenance
therapy, one patient experienced stable disease after the ﬁrst
cycle of vaccination; and later, complete tumor remission
with duration of 3 months. This might be due to the patient
developed neutralizing antibodies in the early stage. Nor-
mally, neutralizing antibodies appeared within 5 to 29 days.
Infectious NDV was recovered from blood, urine, and saliva
samples and have a tumor biopsy sample. Administration of8 Journal of Biomedicine and Biotechnology
strain HUJ caused mild side eﬀects to the patients, including
grade I/II constitutional fever and headache. Sometimes,
the patients might experience neurological problems and
thrombosis. Intravenous administration of NDV strain HUJ
vaccine is well tolerated. The encouraging responses of stain
HUJwarranttheevaluationofNDVinothercancers,besides
GBM [87].
Another lentogenic strain, LaSota was also shown to
induce antitumor cytotoxic eﬀects of mouse macrophages
by the production of TNF-α [33]. The anticancer activity
of activated monocytes was attributed to tumor necrosis
factor-related apoptosis-inducing ligand (TRAIL) [33]. In
the study by Liang et al. [71], vaccination of NDV strain
LaSota was eﬃcient to prolong colorectal cancer patients’
life, with 96% patient survival after 1-year treatment with
NDV immunotherapy. Moreover, the number of NK cells
increased, and immune function obviously improved.
For NDV strain Italien, Ahlert and Schirrmacher [88]
showed that this lytic strain could replicate in diﬀerent
human tumor cells, such as carcinoma of breast, squamous
lung, kidney, melanoma, and lymphoma. Intratumoral
injection of NDV strain Italien displayed high sensitivity
to human metastatic melanoma xenotransplants in nude
mice [48]. There was an MTD in mice in the range of
2000 HAU virus strain Italien [89]. However, nonlytic strain
Ulster showed stronger cytotoxicity eﬀect on a CT26 colon
carcinoma model [48]. This suggested that the antitumor
eﬀect on diﬀerent tumor cells was correlated with the
NDV virulence. Importantly, NDV virus replication did not
happen in normal cells, including resting T lymphocytes and
normal chicken liver cells [20].
13.GeneticallyModiﬁedNDVStrains
Recently, the antitumor eﬃcacy is improved with the new
emerging idea of using recombinant NDV with a therapeutic
gene. To enhance the immunostimulatory properties of
NDV, the IL-2 gene was introduced into the viral coding
sequence [90, 91]. Thus, virus infection leads to production
of IL-2 and initiates immunological eﬀects, including T-cells
activation and IFN-γ production. In vivo, colon carcinoma
tumor-bearing mice treated with recombinant NDV-IL-2
showed signiﬁcant tumor regression and T-cells inﬁltration
90. Ex vivo, the NDV-IL-2 oncolysate resulted in activation
of tumor-speciﬁc CTL and memory T cells [90].
In another study, Janke et al. [51] inserted a recombinant
granule-macrophage colony-stimulating factor (GM-CSF)
as an additional transcription unit into NDV, in order to
augment antitumor immunity. Vaccination of recombinant
virus stimulated human PBMC to exert antitumor eﬀects.
Furthermore, higher synthesis of IFN-α was observed, most
probably contributed by activated monocytes and dendritic
cells [51]. Indirectly, TH immunity was enhanced also.
Later, generation of a recombinant NDV expressing
inﬂuenza NS1 protein, a protein exhibiting IFN-antagonist,
was reported. As a result, the virus enhanced its ability to
form syncytia and lysis eﬀe c to nt u m o rc e l l si nh u m a na n d
animal models, thus resulted in higher overall long-term
survival. Besides, vaccination of recombinant NDV led to
high degree of T-cell inﬁltration, suggesting the generation
of the tumor-speciﬁc CTL response [92].
Another recombinant NDV strain was designed by
Bian et al. [89], in which the virus was modiﬁed by
preincubation with a recombinant bispeciﬁc protein (IL-2
receptor). A new binding site was introduced to the virus;
which enhanced its interaction to tumor-associated target.
Higher virus replication eﬃciency was noticed in the Eb-M7
(IL-2 receptor positive) syngeneic tumor-bearing mice [89].
Administration of modiﬁed NDV revealed that side eﬀects
were reduced without aﬀecting the antitumor activity.
Inconclusion,geneticallymodiﬁedNDVstrainmayhave
notonlyantitumoreﬀect,butalsoaugmentedimmunomod-
ulatory eﬀect. Previous study showed that the recombinant
NDV had high eﬃciency to deliver therapeutic eﬀects,
without aﬀecting oncolytic activities. This proved that NDV
is a high potent vector. Importantly, the virus does not cause
pathogenicity.
14. Involvement of MalaysianIsolates of
NDV StrainsinCancer Research
The oncolytic eﬀects of several local NDV strains, including
AF2240, 01/C, Ijuk, S, F, V4-UPM strains, on human cancer
cell lines, such as CEM-SS (T-lymphoblastic leukemia cells),
HT-29 (colorectal cancer), MCF-7 and MDA-231 (breast
cancer), and HL-60 (acute promyelocytic leukemia) had
been reviewed by Omar et al. [26]. Othman et al. [93]
reported that NDV AF2240 selectively targeted estrogen
dependent cancer cells, such as MCF-7 breast cancer cells.
F strain displayed signiﬁcant oncolytic eﬀects on MDA-
231 and MCF-7 cells, but Ijuk killed MDA-231 cells only.
A study by Zulkiﬂi et al. [94] showed that the V4-UPM
strain displayed oncolytic eﬀects against human malignant
gliomas (DBTRG.05MG and U-87MG) in tissue culture.
Complete regression of U-87 MG gliomas tumor-bearing
mice was observed also. In vivo, intratumoral treatment
using NDV strain AF2240 in human breast cancer cell
xenotransplanted mice caused partial regression [95]. The
virus was detected in the breast tumor sites [96]. However,
the virus was disseminated to normal organs (e.g., liver),
following intratumoral infusion. Virus dissemination may
aﬀect the gene therapy eﬃciency by reducing transgene
expression in the tumor, by accumulating in the normal
tissues [97].
15. Safety of NDV Administration as
Anticancer Agent
Previous studies of utilizing NDV strains as anticancer agent
have resulted in encouraging results. Scientists are interested
in the therapeutic eﬀect of NDV, because of its tumor-
selectivity [18]. NDV strains can selectively replicate up
to 10000 times better in tumor cells, but not in normal
cells [54]. Numerous reports had shown that the virus
cannot replicate in nontransformed cells, such as ﬁbroblast
cells, resting T lymphocytes, and normal primary cultureJournal of Biomedicine and Biotechnology 9
[20, 54, 55, 83]. Besides, NDV is an immunostimulatory
agent, as it can induce antitumor activities of a variety of
eﬀector cells, including NK cells, macrophages, and CTL
[32, 33, 36, 47].
Prior to human clinical trials, the public may question
the safety issues of the vaccine. There is an extensive
safety database for NDV, primarily from dose escalation
trials. All vaccinations are well tolerated in human studies.
According to Pecora et al. [19], oncolytic NDV strain is well
tolerated in doses of at least 3 × 109 infectious units by the
intravenousrouteandatleast4 ×1012 infectiousunitsbythe
intratumoral route. While, the MTD of initial desensitized
dose at 12 × 109 pfu/m2; subsequent infusions were tolerated
up to 10 folds, at 120 × 109 pfu/m2 [19, 78]. Up to now,
there is no report on accumulative toxicity associated with
repeating vaccinations with NDV as evidenced by one cancer
patient who received over 30 courses of PV701 without
recording any adverse events. Basically, the virus was able to
clear from the body within three weeks [19].
Also, the safety and eﬃciency of NDV vaccination is
deduced from improvement of the cancer patients’ survival
rate. Ockert et al. [69] had reported the ﬁve-year survival
beneﬁts in phase II trials involving patients with locally
advanced colorectal carcinoma. Another study by Karcher et
al.[75]revealed61%ofvaccinatedpatientswithstageIIIand
stageIVheadandnecksquamouscellcarcinomaexperienced
increase of ﬁve-year survival rates. So far, many cases of
tumor regression had occurred in NDV-vaccinated patients.
In a glioblastoma patient with resection, complete remission
was observed after several months’ vaccination with ATV-
NDV [70]. The therapy therefore has promising antitumoral
activities in patients.
In addition, NDV vaccination augmented human anti-
tumor immunity, especially tumor-speciﬁc CTL activities,
increasedDTHresponses[61,65,67].Literally,thebestDTH
skin reaction was obtained using a vaccine, comprising of
107 t u m o rc e l l sa n d3 2H A UN D V[ 66, 67]. It caused a
median induration of 8 mm on the vaccination site. The
DTHresponsestothevaccineincreasedthroughoutrepeated
vaccinations. Especially encouraging is that the vaccinated
patients acquired neutralizing antibodies to NDV [19].
In fact, NDV may infect human and cause mild side
eﬀects. Through the experience with farmers and laboratory
researchers, NDV infection produces only minimal disease.
The general side eﬀects displayed on vaccinated patients
are conjunctivitis, laryngitis, hypotension, and mild ﬂu-like
symptoms, including fever (up to 38◦C), chills, tiredness,
headache, muscle pain, and weakness [69, 72, 73]. On
the vaccination sites, erythema, swelling, induration, and
itching were observed [69, 73]. Other typical side eﬀects
observed in some patients were leucopenia and neuropenia.
Occasionally, virus infection was associated with transient
thrombocytopenia and diﬀuse vascular leakage [19]. These
side eﬀects are temporary and disappear in 1 to 2 days after
vaccinations.
Unfortunately, one possibly treatment-related death
involved an old patient with renal carcinoma metastatic
to the lungs and compromised pulmonary function [19].
Postmortem revealed inﬂammation occurred in the tumor-
bearing lung, suggesting rapid tumor lysis leading to fatal
respiratory failure after desensitized vaccination. This raises
thesafetychallengeofNDVvaccineadministrationincancer
patients. Hence, the US Food and Drug Administration
(FDA) has not approve NDV as a cancer treatment until
today.
In conclusion, the safety of NDV strains as anticancer
agent has been consistently high with low toxicity. Although
NDV therapy causes mild side eﬀects, the responses are
negligible as the quality of life of the vaccinated patients
is not aﬀected in negative manner. Despite applications in
thousands of people, NDV vaccination has not caused any
severe adverse eﬀects. This explains the renewed interest in
NDV as an anticancer agent [18].
16. Conclusion
Basedonallthepreviousresearch,NDVissafeandfeasibleto
be used as a therapeutic agent. More systemic investigations
are necessary to enhance the quality and eﬃcacy of NDV
vaccine. Further testing or even preparation of a DNA
vaccine may be required to conﬁrm the safety of virus
administration and to improve the public’s acceptance. In
short, NDV can be a potential alternative adjuvant in cancer
treatment.
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